Integra LifeSciences to Present at Healthcare Conferences in September 2018

PLAINSBORO, N.J., Aug. 15, 2018 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will present at the following healthcare conferences in September:

• On Thursday, September 6, 2018 at 8:35 a.m. ET, Glenn Coleman, chief financial officer will present at the Wells Fargo 2018 Healthcare Conference in Boston, MA. The session will be available through live audio webcast and can be accessed from the Investor section of www.integralife.com.   
• On Thursday, September 13, 2018 at 2:05 p.m. ET, Peter Arduini, president and chief executive officer, will present at the Morgan Stanley 16th Annual Healthcare Conference in New York, NY. The session will be available through live audio webcast and can be accessed from the Investor section of www.integralife.com.

About Integra LifeSciencesIntegra LifeSciences is a global leader in regenerative technologies, neurosurgical and extremity orthopedic solutions dedicated to limiting uncertainty for clinicians, so they can focus on providing the best patient care. Integra offers a comprehensive portfolio of high quality, leadership brands that include AmnioExcel®, Bactiseal®, Cadence®, CertasTM, Codman®, CUSA®, DuraGen®, DuraSeal®, ICP Express®, Integra®, MediHoney®, MicroFrance®, PriMatrix®, Salto Talaris®, SurgiMend®, TCC-EZ®, Titan™ and VersaTru™.  For the latest news and information about Integra and its brands, please visit www.integralife.com.

Statements made at the upcoming conferences may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to, future financial performance, new product development, governmental approvals, market potential and resulting sales as well as potential therapeutic applications, and additional acquisitions. These risks and uncertainties include market conditions and other factors beyond the Company's control and the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2017 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results. These forward-looking statements are made only as the date thereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contacts:
Sravan Emany
Vice President, Treasury & Investor Relations
(609) 936-2488
[email protected]
Michael Beaulieu
Director, Investor Relations
(609) 750-2827
[email protected]
Media Contact:
Laurene Isip
Senior Director, Global Corporate Communications
(609) 750-7984
[email protected]

Source: Integra LifeSciences Holdings Corporation

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Tenax shares Phase 3 LEVEL trial data at ESC Congress 2026
• BranchOut Food raises $2.5M in public stock offering
• Mint Incorporation closes $2.5M registered direct offering